NZ551146A - Desulphatohirudin for treating prevascularised metastasised tumors - Google Patents

Desulphatohirudin for treating prevascularised metastasised tumors

Info

Publication number
NZ551146A
NZ551146A NZ551146A NZ55114605A NZ551146A NZ 551146 A NZ551146 A NZ 551146A NZ 551146 A NZ551146 A NZ 551146A NZ 55114605 A NZ55114605 A NZ 55114605A NZ 551146 A NZ551146 A NZ 551146A
Authority
NZ
New Zealand
Prior art keywords
glu
gly
asn
leu
xaa
Prior art date
Application number
NZ551146A
Other languages
English (en)
Inventor
Cheng-Der Tony Yu
Original Assignee
Canyon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Canyon Pharmaceuticals Inc filed Critical Canyon Pharmaceuticals Inc
Publication of NZ551146A publication Critical patent/NZ551146A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A61K38/58—Protease inhibitors from animals; from humans from leeches, e.g. hirudin, eglin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
NZ551146A 2004-04-12 2005-04-05 Desulphatohirudin for treating prevascularised metastasised tumors NZ551146A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56174104P 2004-04-12 2004-04-12
PCT/US2005/011549 WO2005099749A2 (en) 2004-04-12 2005-04-05 Methods for controlling angiogenesis and cell proliferation

Publications (1)

Publication Number Publication Date
NZ551146A true NZ551146A (en) 2009-04-30

Family

ID=35150501

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ551146A NZ551146A (en) 2004-04-12 2005-04-05 Desulphatohirudin for treating prevascularised metastasised tumors

Country Status (13)

Country Link
US (3) US7795205B2 (enExample)
EP (1) EP1753291A4 (enExample)
JP (1) JP2007532646A (enExample)
AU (1) AU2005232625B2 (enExample)
BR (1) BRPI0509876A (enExample)
CA (1) CA2562756C (enExample)
IL (1) IL178578A (enExample)
MY (1) MY146091A (enExample)
NZ (1) NZ551146A (enExample)
SG (1) SG160323A1 (enExample)
TW (1) TWI362941B (enExample)
WO (1) WO2005099749A2 (enExample)
ZA (1) ZA200609219B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7795205B2 (en) * 2004-04-12 2010-09-14 Canyon Pharmaceuticals, Inc. Methods for effecting regression of tumor mass and size in a metastasized pancreatic tumor
WO2006045503A1 (en) 2004-10-19 2006-05-04 Lonza Ag Method for solid phase peptide synthesis
US20100239627A1 (en) * 2009-03-20 2010-09-23 Wilson Kurt Whitekettle Quarternary ammonium salts delivery systems
US20100239630A1 (en) * 2009-03-20 2010-09-23 Wilson Kurt Whitekettle Phosphonium salts delivery systems
US20100239626A1 (en) * 2009-03-20 2010-09-23 Wilson Kurt Whitekettle Propanediol delivery systems
US20100239651A1 (en) * 2009-03-20 2010-09-23 Wilson Kurt Whitekettle Nitrilopropionamide delivery systems
US20100239650A1 (en) * 2009-03-20 2010-09-23 Wilson Kurt Whitekettle Isothiazolin biodelivery systems
US7803762B1 (en) 2009-08-20 2010-09-28 The Medicines Company Ready-to-use bivalirudin compositions
US7985733B1 (en) 2010-01-06 2011-07-26 The Medicines Company Buffer-based method for preparing bivalirudin drug product
CN104906037A (zh) * 2015-06-23 2015-09-16 广西复鑫益生物科技有限公司平南分公司 一种重组水蛭素滴眼液及其制备方法
CN110404060A (zh) * 2018-04-28 2019-11-05 复旦大学 凝血酶抑制剂在制备抗肿瘤侵袭转移药物中的用途

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU178398B (en) 1979-06-12 1982-04-28 Gyogyszerkutato Intezet Process for producing new agmatine derivatives of activity against haemagglutination
DE3586333T2 (de) 1984-03-27 1992-12-10 Transgene Sa Expressionsvektoren fuer hirudin, transformierte zellen und verfahren zur herstellung von hirudin.
DE3438296A1 (de) 1984-04-18 1985-11-07 Hoechst Ag, 6230 Frankfurt Neue polypeptide mit blutgerinnungshemmender wirkung, verfahren zu deren herstellung bzw. gewinnung, deren verwendung und diese enthaltende mittel
ATE64956T1 (de) 1984-06-14 1991-07-15 Ciba Geigy Ag Verfahren zur herstellung von thrombininhibitoren.
DE3445532A1 (de) 1984-12-13 1986-06-19 Plantorgan Werk Heinrich G.E. Christensen, KG, 2903 Bad Zwischenahn Hirudin-pa, desulfatohirudine-pa, verfahren zur herstellung und pharmazeutische mittel, die diese wirkstoffe enthalten
HU192646B (en) 1984-12-21 1987-06-29 Gyogyszerkutato Intezet Process for preparing new n-alkyl-peptide aldehydes
CA1341029C (en) 1985-02-04 2000-06-20 Michael Kolb Peptidase inhibitors
DE3738541A1 (de) 1987-11-13 1989-05-24 Hoechst Ag Verfahren zur isolierung und reinigung von hirudin
FR2593518B1 (fr) 1985-05-02 1989-09-08 Transgene Sa Vecteurs d'expression et de secretion de l'hirudine par les levures transformees
MY101203A (en) 1985-12-12 1991-08-17 Ucp Gen Pharma Ag Production of thrombin iinhibitors.
MC1834A1 (fr) 1986-07-10 1988-06-03 Transgene Sa Bloc fonctionnel d'adn et plasmide codant pour l'hirudine,levure transformee,procede de preparation de l'hirudine,hirudine obtenue et son utilisation
US5352664A (en) 1986-10-31 1994-10-04 Board Of Regents, The University Of Texas System Thrombin derived polypeptides; compositions and methods for use
US5187157A (en) 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
AU604925B2 (en) 1988-02-23 1991-01-03 Schering Aktiengesellschaft A hirudin derivative
AU614121B2 (en) 1988-05-04 1991-08-22 Novartis Ag Improvements in the production of polypeptides
GB8817161D0 (en) 1988-07-19 1988-08-24 Ciba Geigy Ag Modified proteins
GB8817160D0 (en) 1988-07-19 1988-08-24 Ciba Geigy Ag Novel proteins
EP0362002B1 (en) 1988-09-01 1995-07-26 Merrell Dow Pharmaceuticals Inc. HIV protease inhibitors
JPH04500802A (ja) * 1988-09-29 1992-02-13 バイオジェン インコーポレイテッド ヒルジンペプチド
ZA897514B (en) 1988-10-07 1990-06-27 Merrell Dow Pharma Novel peptidase inhibitors
FR2645175B1 (fr) 1989-03-31 1994-02-18 Transgene Sa Souche de saccharomyces cerevisiaeproductrice d'une proteine heterologue et procede de preparation de ladite proteine heterologue par fermentation de ladite souche
US5096092A (en) * 1990-03-13 1992-03-17 Mmm, Ltd. Food dispensing apparatus utilizing inflatable bladder
TW201303B (enExample) 1990-07-05 1993-03-01 Hoffmann La Roche
ATE140929T1 (de) 1990-11-08 1996-08-15 Japan Energy Corp Hirudinmutante, deren herstellung, antikoagulans, sekretorischer vektor, durch besagten vektor transformierter mikroorganismus und herstellung eines produkts durch besagten mikroorganismus
DE4041185A1 (de) * 1990-12-21 1992-06-25 Knoll Ag Verwendung von hirudin und dessen muteinen zur kombinationsbehandlung von tumoren
AU659432B2 (en) 1991-03-08 1995-05-18 Novartis Ag A method for the inhibition or prevention of tumor cell metastasis with hirudin
CA2075154A1 (en) 1991-08-06 1993-02-07 Neelakantan Balasubramanian Peptide aldehydes as antithrombotic agents
SE9102462D0 (sv) 1991-08-28 1991-08-28 Astra Ab New isosteric peptides
CZ333492A3 (en) 1991-11-12 1993-09-15 Lilly Co Eli Dipeptide of l-azetidine-2-carboxylic acids and l-argininaldehyde, process of its preparation and pharmaceutical preparation in which said dipeptide is comprised
SE9103612D0 (sv) 1991-12-04 1991-12-04 Astra Ab New peptide derivatives
EP0629212B1 (en) 1992-03-04 1997-10-08 Gyogyszerkutato Intezet Kft. New anticoagulant peptide derivatives and pharmaceutical compositions containing the same as well as a process for the preparation thereof
TW223629B (enExample) 1992-03-06 1994-05-11 Hoffmann La Roche
ATE196927T1 (de) 1992-09-04 2000-10-15 Novartis Ag Verfahren zur herstellung von proteaseinhibitoren
AU675981B2 (en) 1992-12-02 1997-02-27 Bristol-Myers Squibb Company Guanidinyl-substituted heterocyclic thrombin inhibitors
GB9303275D0 (en) 1993-02-18 1993-04-07 Ciba Geigy Ag Pharmaceutical compositions
SE9301916D0 (sv) 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
DE4321444A1 (de) 1993-06-28 1995-01-05 Bernd Prof Dr Clement Pharmazeutische Zubereitung
EP0648780A1 (en) 1993-08-26 1995-04-19 Bristol-Myers Squibb Company Heterocyclic thrombin inhibitors
TW394760B (en) 1993-09-07 2000-06-21 Hoffmann La Roche Novel Carboxamides, process for their preparation and pharmaceutical composition containing the same
GB9401448D0 (en) 1994-01-26 1994-03-23 Ciba Geigy Ag Stable dry powders
GB9401447D0 (en) 1994-01-26 1994-03-23 Ciba Geigy Ag Pharmaceutical compositions
CA2140598C (en) 1994-01-27 2010-03-09 Masahiro Ohshima Prolineamide derivatives
IL112795A (en) 1994-03-04 2001-01-28 Astrazeneca Ab Peptide derivatives as antithrombic agents their preparation and pharmaceutical compositions containing them
US5561146A (en) 1994-06-10 1996-10-01 Bristol-Myers Squibb Company Modified guanidino and amidino thrombin inhibitors
DE4421052A1 (de) 1994-06-17 1995-12-21 Basf Ag Neue Thrombininhibitoren, ihre Herstellung und Verwendung
US5843925A (en) 1994-12-13 1998-12-01 American Cyanamid Company Methods for inhibiting angiogenesis, proliferation of endothelial or tumor cells and tumor growth
EP0873356A1 (de) 1995-02-17 1998-10-28 Basf Aktiengesellschaft Neue dipeptidische amidine als thrombin-inhibitoren
SE9600216D0 (sv) 1996-01-18 1996-01-18 Hans Arne Hansson Styrning av läkningsprocesser
PL329851A1 (en) 1996-05-01 1999-04-12 Lilly Co Eli Treatment of diseases associated with vegf
US6573256B2 (en) 1996-12-30 2003-06-03 Bone Care International, Inc. Method of inhibiting angiogenesis using active vitamin D analogues
US6537585B1 (en) * 1999-03-26 2003-03-25 Guilford Pharmaceuticals, Inc. Methods and compositions for treating solid tumors
DE10033195A1 (de) 2000-07-07 2002-03-21 Aventis Pharma Gmbh Bifunktionale Fusionsproteine aus Hirudin und TAP
US6696483B2 (en) 2000-10-03 2004-02-24 Oncopharmaceutical, Inc. Inhibitors of angiogenesis and tumor growth for local and systemic administration
US6476068B1 (en) * 2001-12-06 2002-11-05 Pharmacia Italia, S.P.A. Platinum derivative pharmaceutical formulations
US7795205B2 (en) * 2004-04-12 2010-09-14 Canyon Pharmaceuticals, Inc. Methods for effecting regression of tumor mass and size in a metastasized pancreatic tumor

Also Published As

Publication number Publication date
IL178578A (en) 2013-06-27
US20110224150A1 (en) 2011-09-15
WO2005099749A2 (en) 2005-10-27
AU2005232625B2 (en) 2011-07-28
SG160323A1 (en) 2010-04-29
EP1753291A4 (en) 2009-08-12
CA2562756A1 (en) 2005-10-27
TWI362941B (en) 2012-05-01
IL178578A0 (en) 2007-02-11
US7795205B2 (en) 2010-09-14
ZA200609219B (en) 2012-02-29
US20050233966A1 (en) 2005-10-20
JP2007532646A (ja) 2007-11-15
US20090269422A1 (en) 2009-10-29
TW200538466A (en) 2005-12-01
BRPI0509876A (pt) 2007-10-16
EP1753291A2 (en) 2007-02-21
AU2005232625A1 (en) 2005-10-27
WO2005099749A3 (en) 2006-08-03
MY146091A (en) 2012-06-29
CA2562756C (en) 2011-08-23

Similar Documents

Publication Publication Date Title
US20110224150A1 (en) Methods for effecting regression of tumor mass and size in a metastasized tumor
CA2122519C (en) Cancer treatment and metastasis prevention
KR20110092351A (ko) 방사선 및 화학요법 손상에서 사용되는 국소적 활성 스테로이드
US20250134836A1 (en) Pharmaceutical Composition for Preventing or Treating Cancer, Comprising Gossypol, Phenformin, and Anticancer Agent
CN104800858B (zh) Hsp90抑制肽偶联物及其在肿瘤治疗中的应用
KR20080030559A (ko) 비뇨 생식기암 및 이의 전이 치료용 비소산, 이것의나트륨염 및 이것의 유도체를 함유하는 약학 조성물
EP1496909B1 (en) Combination therapy for the treatment of cancer
CA2709027A1 (en) Treatment of melanoma with alpha thymosin peptides in combination with antibodies against cytotoxic t lymphocyte-associated antigen 4 (ctla4)
AU2008338594A1 (en) Treatment of melanoma with alpha thymosin peptides in combination with an antineoplastic heat shock apoptosis activator (HSAA)
WO2002085117A1 (en) Methods and compositions for preventing and treating septic shock and endotoxemia
JP6782932B2 (ja) Ｎｐｒ−ａアゴニストの新規用途
JP2000506502A (ja) ヒアルロン酸レセプター結合剤、およびその使用方法
JP6038795B2 (ja) ナトリウム利尿ペプチド受容体ｇｃ−ａアゴニスト及びｇｃ−ｂアゴニストを組み合わせてなる悪性腫瘍の増悪防止用医薬
EP3787661B1 (en) Combination of temozolomide and a par-1 conjugate for treating glioblastoma
CN116327772B (zh) SMO抑制剂Sonidegib对管腔型乳腺癌骨转移的靶向治疗方法
EP4506015A1 (en) Combination of a mps1 inhibitor and an antibody drug conjugate
JP2009046450A (ja) 抗がん剤へのヒアルロン酸添加
KR20240041399A (ko) 항암 활성을 갖는 신규한 펩타이드 및 이의 용도
TWI439266B (zh) 對癌症之治療有貢獻的方法和組成物
CA3155360A1 (en) Methods and compositions for treating endometriosis
HK1071310B (en) Combination therapy for the treatment of cancer

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
LAPS Patent lapsed